Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.87 |
| ▸ | MLNR | O43193 | 1/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.87 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.87 |
| ▸ | CCKAR | P32238 | 1/20 | 0.87 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.87 |
| ▸ | GHSR | Q92847 | 1/20 | 0.87 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.87 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.87 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | CTSD | P07339 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | PSMB11 | A5LHX3 | 4/20 | 0.40 |
| ▸ | PSMA7 | O14818 | 4/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.40 |
| ▸ | PSMA1 | P25786 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7946963 | 1.00 | UGT1A1 (0.87) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL825777 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL41696 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL9975220 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL41697 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1559640 | 0.93 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180353609-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2018-12-13 | — | — | US | disclosed |
| US-10092656-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2017-02-02 | — | — | US | disclosed |
| US-20120108501-A1 | Protease Inhibitors | NEKTAR THERAPEUTICS (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2440249-A2 | COVALENT CONJUGATES COMPRISING A PROTEASE INHIBITOR, A WATER-SOLUBLE, NON-PEPTIDIC OLIGOMER AND A LIPOPHILIC MOIETY | Nektar Therapeutics (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | NEKTAR THERAPEUTICS (CA) | 2011-08-11 | — | — | US | disclosed |
| WO-2010144869-A2 | PROTEASE INHIBITORS | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | UGT1A1 136/4885MLNR 1216/4885NR1I2 207/4885 |
| US-10092656-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | UGT1A1 136/4885MLNR 1216/4885NR1I2 207/4885 |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | UGT1A1 136/4885MLNR 1216/4885NR1I2 207/4885 |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | CYP3A43, HPN, ANPEP | UGT1A1 100/4885MLNR 1332/4885NR1I2 473/4885 |
| US-20120108501-A1 | Protease Inhibitors | DNPEP, ADAM17, PREP | UGT1A1 2204/4885MLNR 692/4885NR1I2 2143/4885 |
| US-20180353609-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | UGT1A1 136/4885MLNR 1216/4885NR1I2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.